FOLLOW US

A transatlantic corporate courtship has come to a screeching halt. Less than four weeks after Bain Capital hinted at acquiring Scottish healthcare software maker Craneware, the private equity titan backed out of a potential $1.3 billion deal on Wednesday, sending ripples through the tech and investment communities.

In a brief but telling statement filed with the London Stock Exchange, Bain confirmed it would not move forward with a formal offer. The announcement puts to rest the speculation ignited by Bain's May 16 notice that it was “assessing a possible offer” to scoop up all of Craneware’s shares.

Deal Breakdown: A Bid Rejected at the Gate

Craneware quickly followed with its own declaration, dropping a bombshell: it had already rejected Bain’s proposal, which pegged the company's value at £26.50 per share, or nearly $1.3 billion based on its outstanding shares.

"The board believes that the proposal received from Bain is not in the best interest of shareholders," Craneware said, arguing the bid “fundamentally undervalues Craneware and its prospects.”

The board further emphasized that it remained “fully confident” in the company’s ongoing strategy and long-term ability to deliver substantial shareholder value.

Missed Connection: No Due Diligence, No Deal

Adding to the intrigue, Craneware noted that Bain’s offer was unsolicited and made without the benefit of due diligence, suggesting there was minimal engagement between the two sides. The lack of deeper discussions or financial exploration may have sealed the fate of the transaction before it truly began.

Craneware’s investment banking adviser on the matter is Peel Hunt LLP, though Bain's legal and financial representatives remain unidentified as of press time.

Market Reaction and Company Performance

On Wednesday, Craneware’s shares dipped slightly by 0.75%, capping a day of muted investor response. Although the company saw a brief stock surge in mid-May following Bain's initial interest, its shares are still down approximately 17% over the past year.

Craneware addressed this downturn directly, suggesting that the slump reflects broader market turbulence rather than weaknesses in its core operations.

"The board believes the company's share price performance over the last 12 months is not reflective of the company's trading performance," Craneware said, highlighting “strong trading so far this year”, with growth in revenue, adjusted EBITDA, and other key financial indicators.

What’s Next for Craneware?

Despite walking away from what could’ve been a transformative acquisition, Craneware appears unshaken. The company is doubling down on its internal roadmap, confident that its trajectory in the healthcare software sector—where it provides revenue cycle and cost management tools to hospitals and health systems—remains strong and upward-bound.

As the dust settles, one thing is clear: in a market driven by bold takeovers and billion-dollar buyouts, Craneware chose independence over undervaluation, and Bain Capital—at least for now—missed its shot.